In a multicenter trial of Simvastatin treatment, 49 patients with hypercholesterolemia received the drug orally at 5mg once a day after dinner for 12 months.
The plasma concentrations of total cholesterol and low densityl lipoprotein (1.006∼1.063mg/ml, ultracentrifugation) decreased by 24.7±11.2% and 31.0±8.9%, respectively.
The high density lipoprotein cholesterol levels initially below 40mg/dl tended to increase, although those initially over 40mg/dl did not change significantly.
The plasma concentrations of apoB and apoE decreased markedly but those of apoA1, A2, C2 and C3 did not change. The plasma Lp (a) concentration decreased monthly and the maximum rate of decrease was 35±28.4%.
Lipoprotein lipase activity decreased 6M after drug administration but after 12M it increased to the initial level.
The LDL-cholesterol/apoB ratio decreased markedly, suggesting that LDL molecular size was reduced.
No clinical adverse effects were observed in the 49 cases and general chemical examination showed an increase in GPT value from 23 U to 43 U in one case following a continuous course. The abnormal value was eventually normalized.
View full abstract